Journal article
Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy?
Diabetes care, Vol.30(10), pp.2613-2618
10/2007
DOI: 10.2337/dc07-0850
PMCID: PMC2657957
PMID: 17644617
Abstract
We sought to evaluate the prevalence of subclinical neuropathy in intensive and conventional treatment groups at completion of the Diabetes Control and Complications Trial (DCCT). We assessed neuropathy using nerve conduction results obtained at DCCT completion after stratifying the DCCT cohort to exclude subjects with progressively less severe degrees of diagnosable neuropathy. We began with those who had confirmed clinical neuropathy (the primary DCCT end point) and eventually excluded all subjects with any clinical or electrodiagnostic evidence of neuropathy. After excluding subjects with confirmed clinical neuropathy at DCCT completion, 8 of 10 nerve conduction measures (including all lower-extremity measures) were significantly improved in the intensive treatment group (O'Brien rank-sum test across all nerve conduction measures, P < 0.0001). Conduction velocity group differences were substantial, and the peroneal conduction velocity averaged 3.1 m/s faster in the intensive compared with the conventional treatment group (45.1 vs. 42.0 m/s, P < 0.0001). Numerous significant differences in median and peroneal motor conduction velocities favoring the intensive treatment group persisted, regardless of the exclusion criteria applied. Intensive and conventional treatment group subjects without diagnosable neuropathy at DCCT completion had significant differences in electrophysiologic measurements favoring the intensive treatment group. Differences in subsequent incident neuropathy between the original treatment groups may reflect, in part, their levels of subclinical neuropathy at DCCT completion, rather than persistent metabolic effects.
Details
- Title: Subtitle
- Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy?
- Creators
- James W Albers - DCCT/EDIC Research Group, Box DCCT/EDIC, Bethesda, MD 20892, USA. jwalbers@umich.eduWilliam H HermanRodica Pop-BusuiCatherine L MartinPatricia ClearyBarbara WaberskiDiabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Intervention and Complications (EDIC) Research Group
- Contributors
- H Culver Boldt (Contributor) - University of Iowa, Ophthalmology and Visual Sciences
- Resource Type
- Journal article
- Publication Details
- Diabetes care, Vol.30(10), pp.2613-2618
- Publisher
- United States
- DOI
- 10.2337/dc07-0850
- PMID
- 17644617
- PMCID
- PMC2657957
- ISSN
- 0149-5992
- eISSN
- 1935-5548
- Grant note
- N01 DK062204-007 / NIDDK NIH HHS
- Language
- English
- Date published
- 10/2007
- Academic Unit
- Ophthalmology and Visual Sciences
- Record Identifier
- 9983979932602771
Metrics
17 Record Views